Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study has the following objectives:
Primary Objective
- To evaluate the anti-lymphoma efficacy of daily oral doses of ITF2357 followed by
intravenous Mechlorethamine administered to patients with refractory/relapsed Hodgkin's
lymphoma.
Secondary Objective
- To evaluate the safety and tolerability of multiple courses of ITF2357 followed by
Mechlorethamine in a population of chemotherapy pretreated patients.